Compare · ARGX vs LXEO
ARGX vs LXEO
Side-by-side comparison of argenx SE (ARGX) and Lexeo Therapeutics Inc. (LXEO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and LXEO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $64.03B, about 163.9x LXEO ($390.5M).
- Both names hit the wire about 10 times in the past 4 weeks.
- ARGX has more recent analyst coverage (25 ratings vs 11 for LXEO).
- Company
- argenx SE
- Lexeo Therapeutics Inc.
- Price
- -
- -
- Market cap
- $64.03B
- $390.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2023
- News (4w)
- 10
- 10
- Recent ratings
- 25
- 11
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Completes Acquisition of Forte Biosciences, Inc.
- argenx upgraded by UBS with a new price target
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Latest LXEO
- Chief Financial Officer Tamayo Louis Edward sold $20,203 worth of shares (4,117 units at $4.91), decreasing direct ownership by 4% to 92,907 units (SEC Form 4) (tax withholding)
- Chief Executive Officer Townsend Richard Nolan sold $16,562 worth of shares (3,345 units at $4.95), decreasing direct ownership by 0.89% to 374,472 units (SEC Form 4) (withholding tax)
- Chief Operating Officer Otero Jose Manuel sold $6,464 worth of shares (1,304 units at $4.96), decreasing direct ownership by 0.95% to 136,178 units (SEC Form 4) (for tax liability)
- SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.
- SEC Form 10-Q filed by Lexeo Therapeutics Inc.
- Lexeo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights